Myron Kaplan - 26 Jan 2026 Form 4 Insider Report for CorMedix Inc. (CRMD)

Reporting relationship: Director
Issuer ticker: CRMD
Reported as of: 26 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2026, 21:30:08 UTC
Prior SEC filing: 27 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Beth Zelnick Kaufman, attorney-in-fact

Key filing fact

Myron Kaplan filed Form 4 for CorMedix Inc. (CRMD) on 27 Jan 2026.

Key facts

This page summarizes Myron Kaplan's Form 4 filing for CorMedix Inc. (CRMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Jan 2026, 21:30.

Change

Previous filing in this sequence was filed on 27 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001672645 Primary reporting owner

Kaplan Myron

Relationship: Director
Address: C/O CORMEDIX INC., 389 INTERPACE PKWY, SUITE 450, PARSIPPANY
Signature: /s/ Beth Zelnick Kaufman, attorney-in-fact
Signature date: 27 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRMD transaction

Common Stock

Award

Transaction value: $0
Shares: +30,453
Change %: +15%
Price: $0.000000
Shares after: 231,487
Date: 26 Jan 2026
Ownership: Direct
Footnotes: F1

CRMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,000
Date: 26 Jan 2026
Ownership: Spouse
Footnotes: F2

CRMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,000
Date: 26 Jan 2026
Ownership: Spouse as Guardian for Grandchildren
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

Footnote F2

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

SEC remarks

Exhibit 24.1 - Power of Attorney